Fibromyalgia and MCS: A Standalone Proteomic Biomarker (TRPA1-Cys621) for LC-MS/MS

Objective laboratory diagnosis of fibromyalgia and Multiple Chemical Sensitivity (MCS) remains one of the greatest unmet needs in clinical medicine, leaving patients without definitive biochemical verification. Building upon our previously published etiopathogenic model (Fibromyalgia: 5 Diagnostic Biomarkers to Test in the Laboratory, Zenodo DOI: 10.5281/zenodo.24210309), this technical communication introduces a sixth, standalone diagnostic biomarker of absolute mathematical precision that overcomes the analytical instability of measuring blood tetrahydrobiopterin (BH4/BH2), which rapidly auto-oxidizes outside the body. The pathology originates from a congenital, unilateral stenosis of the posterior superior alveolar foramen in the maxillary tuberosity, occurring exclusively in the ~30% of the population where the ~1 mm artery follows a submucosal course beneath the Schneiderian membrane—thereby ruling out intraosseous or gingival trajectories. Following estrogen decline, unopposed sympathetic vasoconstriction triggers a hemodynamic Venturi effect that generates superoxide anion, peroxynitrite, and lipid peroxidation aldehydes (4-HNE). To prevent local osteomyelitis and osteonecrosis, the neural crest stem cell-rich maxillary tuberosity continuously consumes L-tryptophan via IDO1 to synthesize kynurenine, which in turn activates TRP channels, overstimulates the neurovegetative and immune systems, and depletes cholesterol and adrenal steroid/cortisol reserves. Through high-resolution tandem mass spectrometry (LC-MS/MS) on maxillary submucosal microbiopsy or 3-mm skin punch biopsy, covalent oxidative modifications on the master nucleophilic residue Cysteine 621 (Cys621) of the human nociceptive and chemosensory channel TRPA1 (UniProt: O75762) are quantified via invariable monoisotopic mass shifts: -2.0157 Da (Cys621–Cys665 disulfide bridge), +31.9898 Da (sulfinic acid), +47.9847 Da (sulfonic acid), and +156.1150 Da (4-HNE adduct). This irreversible molecular signature demonstrates that the channel pore is left completely open and never closes—functioning as a biological switch permanently locked in the "on" position within cutaneous C-fiber free nerve endings that fails to respond to any type of pharmacological treatment—amplifying thermal (cold and heat) and pain signaling. Consequently, it provides a single, unified organic explanation for seemingly nonspecific symptoms—including spontaneous skin pain, severe cutaneous allodynia to clothing or bedsheets, extreme cold and heat hypersensitivity, generalized environmental and chemical intolerance, hyperacusis, tinnitus, vertigo, and burning mouth syndrome—confirming by itself both fibromyalgia and MCS and guiding causal resolution via piezoelectric decompressive osteoplasty.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-16
DOI
https://doi.org/10.5281/zenodo.24272649
Primary Topic
Fibromyalgia and Chronic Fatigue Syndrome Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fibromyalgia and MCS: A Standalone Proteomic Biomarker (TRPA1-Cys621) for LC-MS/MS

Faustino Fernandez
4 links
Zenodo (CERN European Organization for Nuclear Research)
Fibromyalgia and Chronic Fatigue Syndrome Research
article

Fibromyalgia and MCS: A Standalone Proteomic Biomarker (TRPA1-Cys621) for LC-MS/MS

Faustino Fernandez
article en

Abstract

Objective laboratory diagnosis of fibromyalgia and Multiple Chemical Sensitivity (MCS) remains one of the greatest unmet needs in clinical medicine, leaving patients without definitive biochemical verification. Building upon our previously published etiopathogenic model (Fibromyalgia: 5 Diagnostic Biomarkers to Test in the Laboratory, Zenodo DOI: 10.5281/zenodo.24210309), this technical communication introduces a sixth, standalone diagnostic biomarker of absolute mathematical precision that overcomes the analytical instability of measuring blood tetrahydrobiopterin (BH4/BH2), which rapidly auto-oxidizes outside the body. The pathology originates from a congenital, unilateral stenosis of the posterior superior alveolar foramen in the maxillary tuberosity, occurring exclusively in the ~30% of the population where the ~1 mm artery follows a submucosal course beneath the Schneiderian membrane—thereby ruling out intraosseous or gingival trajectories. Following estrogen decline, unopposed sympathetic vasoconstriction triggers a hemodynamic Venturi effect that generates superoxide anion, peroxynitrite, and lipid peroxidation aldehydes (4-HNE). To prevent local osteomyelitis and osteonecrosis, the neural crest stem cell-rich maxillary tuberosity continuously consumes L-tryptophan via IDO1 to synthesize kynurenine, which in turn activates TRP channels, overstimulates the neurovegetative and immune systems, and depletes cholesterol and adrenal steroid/cortisol reserves. Through high-resolution tandem mass spectrometry (LC-MS/MS) on maxillary submucosal microbiopsy or 3-mm skin punch biopsy, covalent oxidative modifications on the master nucleophilic residue Cysteine 621 (Cys621) of the human nociceptive and chemosensory channel TRPA1 (UniProt: O75762) are quantified via invariable monoisotopic mass shifts: -2.0157 Da (Cys621–Cys665 disulfide bridge), +31.9898 Da (sulfinic acid), +47.9847 Da (sulfonic acid), and +156.1150 Da (4-HNE adduct). This irreversible molecular signature demonstrates that the channel pore is left completely open and never closes—functioning as a biological switch permanently locked in the "on" position within cutaneous C-fiber free nerve endings that fails to respond to any type of pharmacological treatment—amplifying thermal (cold and heat) and pain signaling. Consequently, it provides a single, unified organic explanation for seemingly nonspecific symptoms—including spontaneous skin pain, severe cutaneous allodynia to clothing or bedsheets, extreme cold and heat hypersensitivity, generalized environmental and chemical intolerance, hyperacusis, tinnitus, vertigo, and burning mouth syndrome—confirming by itself both fibromyalgia and MCS and guiding causal resolution via piezoelectric decompressive osteoplasty.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Fibromyalgia and Chronic Fatigue Syndrome Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon